Results 61 to 70 of about 76,618 (225)

Biologic treatments in rheumatoid arthritis and juvenile idiopathic arthritis [PDF]

, 2006
A number of biological approaches to the management of inflammtory arthropathies have been explored. These include the development of IL-1 receptor antagonists and TNF antagonists. Four biological agents are currently marketed in Europe.
Borg, Andrew A.
core  

Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of the Phase 3, Randomized, Placebo‐Controlled SOLSTICE Study

Arthritis &Rheumatology, Accepted Article.
Objective Evaluate the efficacy and safety of guselkumab, an interleukin‐23p19‐subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor inhibitor (TNFi‐IR).
Alexis Ogdie, Joseph F Merola, Philip J Mease, Christopher T Ritchlin, Jose U Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B Gottlieb   +12 more
wiley   +1 more source

Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy

Experimental Hematology & Oncology, 2021
Cytokine release syndrome (CRS) is the most common toxicity induced by chimeric antigen receptor (CAR) T cell therapy. At present, anti-IL-6 agents including tocilizumab and siltuximab have been applied in the treatment of CRS.
Lina Zhang, Shuai Wang, Ji Xu, Run Zhang, Han Zhu, Yujie Wu, Liying Zhu, Jianyong Li, Lijuan Chen   +8 more
doaj   +1 more source

Spinal release of tumour necrosis factor activates c-Jun N-terminal kinase and mediates inflammation-induced hypersensitivity. [PDF]

, 2014
BackgroundMounting evidence points to individual contributions of tumour necrosis factor-alpha (TNF) and the c-Jun N-terminal kinase (JNK) pathway to the induction and maintenance of various pain states.
Abdelmoaty, S, Bas, DB, Codeluppi, S, Fitzsimmons, B, Hua, XY, Sandor, K, Steinauer, J, Svensson, CI, Yaksh, TL   +8 more
core   +2 more sources

Facilitating Expedited Drug Approval– the Past, Present, and Future of Clinical Trials for Pediatric Rheumatic Disease

Arthritis Care &Research, Accepted Article.
Pamela F. Weiss, Hermine I. Brunner
wiley   +1 more source

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a long‐term multicenter observational study

Arthritis &Rheumatology, Accepted Article.
Objective Osteoporosis causes fractures which further increase the disease burden of rheumatoid arthritis (RA), however, osteoporosis treatment rates remain low. While several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...
Takafumi Aritomi, Koshiro Sonomoto, Shingo Nakayamada, Hiroaki Tanaka, Atsushi Nagayasu, Satoshi Kubo, Ippei Miyagawa, Ayako Yamaguchi, Naoaki Ohkubo, Yasuyuki Todoroki, Yurie Satoh‐Kanda, Masanobu Ueno, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Satsuki Matsunaga, Hiroaki Tanaka, Masayuki Shinojima, Hiroki Kawamura, Kazuki Takahashi, Miyabi Ando, Kazuki Haru, Yusuke Miyazaki, Kentaro Hanami, Masao Nawata, Shunsuke Fukuyo, Keisuke Nakatsuka, Mikiko Tokunaga, Kazuyoshi Saito, Yoshiya Tanaka   +30 more
wiley   +1 more source

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date. [PDF]

, 2018
Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years in understanding the immune-mediated pathophysiology of psoriasis have led to the development of targeted biologic
Beck, Kristen M, Liao, Wilson, Sanchez, Isabelle M, Yang, Eric J   +3 more
core  

Plasma total antioxidant capacity and peroxidation biomarkers in psoriasis [PDF]

, 2016
Systemic biomarkers of oxidative stress can be relevant for assessment of psoriasis severity, for prediction of the outcome of therapy and of the development of comorbidities.
Cavaliere, Arturo, Palmery, Maura, Peluso, Ilaria   +2 more
core   +2 more sources

Coverage generosity of novel anti‐rheumatic drugs in Medicare Advantage and stand‐alone Part D plans

Arthritis &Rheumatology, Accepted Article.
Objective To examine coverage of self‐administered disease‐modifying anti‐rheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022‐2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T‐cell co‐stimulatory modulator, Interleukin‐6 ...
Youngmin Kwon, Robert W. Corty, Stacie B. Dusetzina   +2 more
wiley   +1 more source

The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy

Journal of Infection and Public Health
Background: The risk of infection including tuberculosis (TB) infection or reactivation during biological therapy with the current various clinical application is a major concern. This risk may be higher in countries endemic to TB.
Abdulaziz Boqaeid, Laila Layqah, Amgad Alonazy, Mutaz Althobaiti, Al-zahraa Almahlawi, Abdullah Al-Roqy, Omar Baharoon, Abdullah Alsaeedi, Jinan Shamou, Salim Baharoon   +9 more
doaj   +1 more source